Page last updated: 2024-12-07

3'-(4-morpholinyl)-3'-deaminodaunorubicin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3'-(4-morpholinyl)-3'-deaminodaunorubicin is a synthetic derivative of daunorubicin that has been investigated as a potential anticancer agent. It exhibits increased activity compared to daunorubicin against certain cancer cell lines, particularly those resistant to daunorubicin. This enhanced activity is attributed to its improved ability to bind to DNA and inhibit DNA synthesis. The compound is synthesized through a multi-step process that involves modification of the daunorubicin molecule. Its effects on cancer cells are primarily mediated through its interaction with DNA, leading to cell cycle arrest and apoptosis. Research into this compound is motivated by the need to develop new and more effective anticancer therapies. The increased activity of 3'-(4-morpholinyl)-3'-deaminodaunorubicin against daunorubicin-resistant cells suggests its potential to overcome drug resistance in cancer treatment.'

3'-(4-morpholinyl)-3'-deaminodaunorubicin: RN given refers to parent cpd(8S-cis)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID93463
MeSH IDM0107145

Synonyms (11)

Synonym
5,12-naphthacenedione, 8-acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-, (8s-cis)-
5,12-naphthacenedione, 7,8,9,10-tetrahydro-8-acetyl-1-methoxy-10-((2,3,6-trideoxy-3-(4-morpholinyl)-alpha-l-lyxo-hexopyranosyl)oxy)-6,8,11-trihydroxy-, (8s-cis)-
brn 5232668
3'-(4-morpholinyl)-3'-deaminodaunorubicin
94730-46-8
9-acetyl-6,9,11-trihydroxy-7-[(2r,4s,5r)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
ccris 5081
79867-78-0
morpholinodaunomycin
DTXSID40915341
3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-morpholin-4-ylhexopyranoside
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.37 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]